Neurogene Stock Market Value
| NGNE Stock | 18.31 0.68 3.58% |
| Symbol | Neurogene |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neurogene 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurogene's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurogene.
| 10/26/2025 |
| 01/24/2026 |
If you would invest 0.00 in Neurogene on October 26, 2025 and sell it all today you would earn a total of 0.00 from holding Neurogene or generate 0.0% return on investment in Neurogene over 90 days. Neurogene is related to or competes with Lineage Cell, Ocugen, Fulcrum Therapeutics, Autolus Therapeutics, ADC Therapeutics, Benitec Biopharma, and Solid Biosciences. Neurogene is entity of United States. It is traded as Stock on NASDAQ exchange. More
Neurogene Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurogene's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurogene upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 23.85 | |||
| Value At Risk | (9.34) | |||
| Potential Upside | 7.26 |
Neurogene Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurogene's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurogene's standard deviation. In reality, there are many statistical measures that can use Neurogene historical prices to predict the future Neurogene's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.21) | |||
| Treynor Ratio | (0.31) |
Neurogene January 24, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 3.91 | |||
| Coefficient Of Variation | (715.86) | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.35 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.21) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 23.85 | |||
| Value At Risk | (9.34) | |||
| Potential Upside | 7.26 | |||
| Skewness | (0.32) | |||
| Kurtosis | 0.7939 |
Neurogene Backtested Returns
Neurogene has Sharpe Ratio of -0.15, which conveys that the firm had a -0.15 % return per unit of risk over the last 3 months. Neurogene exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neurogene's Standard Deviation of 5.13, risk adjusted performance of (0.09), and Mean Deviation of 3.91 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 2.31, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurogene will likely underperform. At this point, Neurogene has a negative expected return of -0.78%. Please make sure to verify Neurogene's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Neurogene performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.68 |
Good predictability
Neurogene has good predictability. Overlapping area represents the amount of predictability between Neurogene time series from 26th of October 2025 to 10th of December 2025 and 10th of December 2025 to 24th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurogene price movement. The serial correlation of 0.68 indicates that around 68.0% of current Neurogene price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.68 | |
| Spearman Rank Test | 0.86 | |
| Residual Average | 0.0 | |
| Price Variance | 1.67 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out Neurogene Correlation, Neurogene Volatility and Neurogene Alpha and Beta module to complement your research on Neurogene. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Neurogene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.